Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

December 28, 2021

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

News Conference News AHA 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

November 14, 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

News Conference News ESC 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

August 28, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction

News Daily News

FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction

Michael O'Riordan

August 19, 2021

Apixaban May Be Best DOAC for Frail, Older Patients With AF

News Daily News

Apixaban May Be Best DOAC for Frail, Older Patients With AF

July 19, 2021

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

FDA Approves Dabigatran for VTE in Children

News Daily News

FDA Approves Dabigatran for VTE in Children

June 22, 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Observational Study Supports Continuing Oral Anticoagulation During PCI

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

DOACs Safe, Effective in Subset of Valvular AF Patients

News Daily News

DOACs Safe, Effective in Subset of Valvular AF Patients

March 31, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.